Email this article 
Reduction in incidence of early fatal complications of high-dose chemotherapy with autologous hematopoietic stem cell transplantation in Hodgkin lymphoma patients
- Authors: Zhukov N.V.1, Uss A.L.2, Milanovich N.F.2, Ptushkin V.V.3, Afanasyev B.V.4, Mikhaylova N.B.4, Larionova V.B.5, Demina E.A.5, Karamanesht E.E.6, Tyurina N.G.7, Pavlova O.A.7, Rumyantsev A.G.3, Kaprin A.D.7
-
Affiliations:
- P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of Russia Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
- National Center of Hematology and Bone Marrow Transplantation
- Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
- Raisa Gorbacheva Memorial Institute of Children Hematology and Transplantation, First Saint Petersburg Pavlov State Medical University, Ministry of Health of Russia
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Kiev Center of Bone Marrow Transplantation
- P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of Russia
- Issue: Vol 8, No 3 (2013)
- Pages: 35-41
- Section: HEMATOPOIETIC STEM CELL TRANSPLANTATION
- Published: 21.08.2013
- URL: https://oncohematology.abvpress.ru/ongm/article/view/24
- DOI: https://doi.org/10.17650/1818-8346-2013-8-3-35-41
- ID: 24
Cite item
Full Text
Abstract
Traditionally, the concern of fatal complication is a major obstacle to transfer patients with unfavorable course of Hodgkin’s lymphoma to
national transplantation centers. Early mortality after high-dose chemotherapy with autologous hematopoietic stem cell transplantation
(HSCT) in the Russia, Ukraine and Belarus was assessed in this retrospective multicenter study.
Patients and methods. The study included 372 patients with unfavorable course of Hodgkin’s lymphoma received HSCT between 01.1990
and 06.2013: 35.5 % patients with primary resistance, 30.6 % with early relapse, 33.1 % with late relapse and 0.8 % during consolidation of
first complete remission.
Results. During first 100 days after HSCT died 14 (3.8 %) patients, during first year – 31 (8.4 %) patients. During the study period a significant decrease in the 100-day and 1-year mortality rate was observed (p < 0.0001 for both). Among patients received HSCT in 1990–
1995, 1996–2000, 2001–2005 and 2006–2013 the 100-day mortality was 19.4 %, 6.3 %, 1.1 % and 0.6 %, respectively. 1-year mortality for the same intervals was 32.3 %, 14.7 %, 4.5 % and 1.9 %, respectively.
Conclusions. Currently HSCT in patients with unfavorable course of Hodgkin's lymphoma in national transplant centers, accompanied by an extremely low risk of fatal toxicity.
About the authors
N. V. Zhukov
P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of RussiaDmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Author for correspondence.
Email: zhukov.nikolay@rambler.ru
Russian Federation
A. L. Uss
National Center of Hematology and Bone Marrow TransplantationRussian Federation
N. F. Milanovich
National Center of Hematology and Bone Marrow TransplantationRussian Federation
V. V. Ptushkin
Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaRussian Federation
B. V. Afanasyev
Raisa Gorbacheva Memorial Institute of Children Hematology and Transplantation, First Saint Petersburg Pavlov State Medical University, Ministry of Health of RussiaRussian Federation
N. B. Mikhaylova
Raisa Gorbacheva Memorial Institute of Children Hematology and Transplantation, First Saint Petersburg Pavlov State Medical University, Ministry of Health of RussiaRussian Federation
V. B. Larionova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesRussian Federation
E. A. Demina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical SciencesRussian Federation
E. E. Karamanesht
Kiev Center of Bone Marrow TransplantationRussian Federation
N. G. Tyurina
P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of RussiaRussian Federation
O. A. Pavlova
P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of RussiaRussian Federation
A. G. Rumyantsev
Dmitriy Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of RussiaRussian Federation
A. D. Kaprin
P.A. Gertsen Moscow Research Institute of Oncology, Ministry of Health of RussiaRussian Federation
References
Supplementary files
